Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib

被引：0
|
作者：
Hua Cheng
She-Juan An
Song Dong
Yi-Fang Zhang
Xu-Chao Zhang
Zhi-Hong Chen
Yi-Long Jian-Su
机构：
[1] Guangdong Lung Cancer Institute; Medical Research Center of Guangdong General Hospital & Guangdong Academy of Medical Sciences,
[2] Thoracic oncology,undefined
[3] the fifth affiliated hospital of Sun Yat-Sen university,undefined
来源：
Journal of Hematology & Oncology | / 4卷
关键词：
Paclitaxel; Gefitinib; Erlotinib; H1650 Cell; Combination Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer
    Masago, Katsuhiro
    Horio, Yoshitsugu
    Fujita, Shiro
    Yatabe, Yasushi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S391 - S394
  • [22] Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines
    Effendi, Wiwin Is
    Nagano, Tatsuya
    Tachihara, Motoko
    Umezawa, Kanoko
    Kiriu, Tatsunori
    Dokuni, Ryota
    Katsurada, Masahiro
    Yamamoto, Masatsugu
    Kobayashi, Kazuyuki
    Nishimura, Yoshihiro
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 3669 - 3679
  • [23] Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer
    Kitagawa, Chiyoe
    Mori, Masahide
    Ichiki, Masao
    Sukoh, Noriaki
    Kada, Akiko
    Saito, Akiko M.
    Ichinose, Yukito
    IN VIVO, 2019, 33 (02): : 477 - 482
  • [24] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [25] Gefitinib Plus Paclitaxel after Failure of Gefitinib in Non-small Cell Lung Cancer Initially Responding to Gefitinib
    Shukuya, Takehito
    Takahashi, Toshiaki
    Tamiya, Akihiro
    Ono, Akira
    Igawa, Satoshi
    Nakamura, Yukiko
    Tsuya, Asuka
    Murakami, Haruyasu
    Naito, Tateaki
    Kaira, Kyoichi
    Endo, Masahiro
    Yamamoto, Nobuyuki
    ANTICANCER RESEARCH, 2009, 29 (07) : 2747 - 2751
  • [26] Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
    Loong, Herbert H.
    Kwan, Sui-chun Sampson
    Mok, Tony Shu-kam
    Lau, Yat-ming
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (11)
  • [27] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [28] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Gen, Soei
    Tanaka, Ichidai
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Hashimoto, Naozumi
    BMC CANCER, 2022, 22 (01)
  • [29] Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells
    Gao, Wen
    Wang, Michael
    Wang, Li
    Lu, Haibo
    Wu, Shuhong
    Dai, Bingbing
    Ou, Zhishuo
    Zhang, Liang
    Heymach, John V.
    Gold, Kathryn A.
    Minna, John
    Roth, Jack A.
    Hofstetter, Wayne L.
    Swisher, Stephen G.
    Fang, Bingliang
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09):
  • [30] Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer
    Yetisir, Abdullah Evren
    Paydas, Semra
    Buyuksimsek, Mahmut
    Ogul, Ali
    Kolsuz, Irem
    Kidi, Mehmet Mutlu
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (01) : 285 - 288
12345